Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
2024 Paris Olympics TV schedule
Recommended
Former Holly Hill Hospital employees say facility tried to fool state inspectors
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gain Therapeutics Inc
(NQ:
GANX
)
1.050
+0.010 (+0.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gain Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
March 26, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at Public Ventures Discovery Day
March 15, 2024
Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb...
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
March 05, 2024
Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
March 05, 2024
Gain Therapeutics' GBA1 Parkinson's disease focused GT-02287's mechanism of action, tackling GCase misfolding to enhance lysosomal activity.
Via
Benzinga
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
February 27, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
February 14, 2024
Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
February 06, 2024
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
February 06, 2024
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
January 31, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 16, 2024
Via
Benzinga
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
January 02, 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
December 04, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
December 01, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
November 29, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
November 24, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 21, 2023
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the...
Via
Benzinga
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
November 21, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
November 20, 2023
Via
Benzinga
Gain Therapeutics Announces Proposed Public Offering
November 20, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023
Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
These Apple Insiders Are Selling Shares of AAPL Stock
October 04, 2023
Apple stock is on the move Wednesday after several insiders at the company, including CEO Tim Cook, sold shares of AAPL.
Via
InvestorPlace
Why Is Nvni Group (NVNI) Stock Down 8% Today?
October 04, 2023
Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger.
Via
InvestorPlace
Why Is Gain Therapeutics (GANX) Stock Moving Today?
October 04, 2023
Gain Therapeutics stock is on the move Wednesday as investors in GANX react to updated clinical trial news from the company.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 04, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday.
Via
InvestorPlace
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
October 04, 2023
First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical development
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
September 25, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
September 20, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
September 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
September 12, 2023
Via
Benzinga
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
Via
Get News
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.